The effects of recombinant tissue-type plasminogen activator (rt-PA) on canine cadaver lung transplantation

[1]  H. Wada,et al.  An evaluation of the tolerance of the autotransplanted canine lung against warm ischemia , 1989, The Japanese journal of surgery.

[2]  H. Nishi.  Successful canine cadaver lung transplantation after 18-hour preservation , 1997 .

[3]  R. Novick,et al.  Lung preservation: the importance of endothelial and alveolar type II cell integrity. , 1996, The Annals of thoracic surgery.

[4]  M. Aoe,et al.  Improved lung function by urokinase infusion in canine lung transplantation using non-heart-beating donors. , 1995, The Annals of thoracic surgery.

[5]  H. Date,et al.  Evaluation of the viability of the canine cadaver lung for transplantation. , 1993, Acta medica Okayama.

[6]  B. Wilcox,et al.  Effect of a free radical scavenger on cadaver lung transplantation. , 1993, The Annals of thoracic surgery.

[7]  B. Wilcox,et al.  Cadaver lung donors: effect of preharvest ventilation on graft function. , 1993, The Annals of thoracic surgery.

[8]  O. H. Lowry,et al.  Changes in alveolar oxygen and carbon dioxide concentration and oxygen consumption during lung preservation. The maintenance of aerobic metabolism during lung preservation. , 1993, The Journal of thoracic and cardiovascular surgery.

[9]  O. H. Lowry,et al.  Evaluation of lung metabolism during successful twenty-four-hour canine lung preservation. , 1993, The Journal of thoracic and cardiovascular surgery.

[10]  E. Braunwald,et al.  Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion , 1993, The Lancet.

[11]  B. Wilcox,et al.  A strategy to increase the donor pool: use of cadaver lungs for transplantation. , 1991, The Annals of thoracic surgery.

[12]  S. Goldhaber.  Thrombolysis for pulmonary embolism. , 1991, Progress in cardiovascular diseases.

[13]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.

[14]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .

[15]  J. Hirsh,et al.  The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. , 1985, Thrombosis research.

[16]  J. Hirsh,et al.  Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. , 1985, Blood.

[17]  J. Hirsh,et al.  A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. , 1985, Circulation.

[18]  P. Petitpretz,et al.  Effects of a single bolus of urokinase in patients with life-threatening pulmonary emboli: a descriptive trial. , 1984, Circulation.

[19]  K. Albertine,et al.  LEUCOCYTES AND PULMONARY MICROVASCULAR INJURY , 1982, Annals of the New York Academy of Sciences.

[20]  M. Hoylaerts,et al.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. , 1982, The Journal of biological chemistry.

[21]  P. Friberger,et al.  13. Plasminogen determination in human plasma , 1982 .

[22]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .